Related Experiment Videos
[Platelet aggregation in patients with coronary disease treated with nifedipine]
W Tkaczewski1, J H Goch, G Kruszyński
1III Kliniki Chorób Wewnetrznych IMW w Lodzi.
Insights
Nifedipine was found to reduce blood platelet aggregation in patients with coronary heart disease. This effect was observed after both single and long-term nifedipine treatments, indicating its potential therapeutic benefit.
Area of Science:
- Cardiology
- Pharmacology
- Hematology
Background:
- Coronary heart disease (CHD) is a significant cardiovascular condition.
- Blood platelet aggregation plays a crucial role in thrombotic events associated with CHD.
- Understanding agents that modulate platelet activity is vital for CHD management.
Purpose of the Study:
- To investigate the impact of nifedipine on blood platelet aggregation in patients diagnosed with coronary heart disease.
- To assess the effects of both acute and chronic nifedipine administration on platelet function.
Main Methods:
- The study included 78 male patients with coronary heart disease (mean age 51 years).
- Platelet aggregation was measured using the Born method, induced by adenosine diphosphate (ADP) at 1 microM/ml and 5 microM/ml concentrations.
- Patients received single doses of 10 mg or 20 mg nifedipine, or a 30 mg daily dose for two weeks.
Main Results:
- Nifedipine demonstrated a reduction in blood platelet aggregation.
- This inhibitory effect on platelet aggregation was evident after both single-dose and two-week treatment regimens.
- The findings suggest nifedipine influences platelet activity in individuals with CHD.
Conclusions:
- Nifedipine effectively reduces blood platelet aggregation in patients suffering from coronary heart disease.
- Both short-term and long-term use of nifedipine show anti-aggregatory properties.
- Nifedipine may serve as a therapeutic option for managing platelet-related complications in CHD.
Abstract:
The effect of nifedipine on the aggregation of blood platelets has been studied in patients with coronary heart disease. The study involved 78 males, aged between 36 and 64 years (mean age 51 years). The level of aggregation was evaluated before and after a single nifedipine dose of 10 mg (in 15 patients) and of 20 mg (in 34 patients) as well as before and after the treatment with nifedipine (of 29 patient) with a daily dose of 30 mg for two weeks. Aggregation of blood platelets induced by adenosine--diphosphate in of concentrations 1 microM/ml and of 5 microM/ml were estimated by the Born method. It was found that nifedipine reduces the aggregation of the blood platelets in patients with coronary heart disease following single and long-term treatment.